How to buy Intuitive Surgical (ISRG) stock from India

Yes, an Indian resident can buy Intuitive Surgical — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%; the 90% that decides your outcome is tax, estate-tax exposure, and position sizing. ISRG has one helpful quirk: no dividend, so US withholding and Form 67 are essentially a non-issue. The short version is below.

The 30-second version

• Legal and simple. Buy ISRG via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole shares or a fractional rupee amount — fractional matters, one share trades in the high hundreds of dollars.
• Pure capital-gains play. ISRG has never paid a cash dividend and reinvests into R&D, da Vinci 5, and Ion/SP, so US dividend withholding and Form 67 are essentially irrelevant.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. This is Section 112, not the friendlier 112A that Indian shares get.
• The trap most miss: directly-held ISRG is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "US medical devices," IHI and XHE hold ISRG as a top weight; QQQ, VOO, and VTI also carry it — same exposure, no single-stock risk.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	ISRG / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional lets you invest an exact rupee amount)
Dividend	None — ISRG has never paid a cash dividend
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN during onboarding — good practice even with no current dividend, because it covers any future distribution. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. ISRG trades in the high hundreds of dollars per share — fractional shares are the practical way to size in rupees rather than chase whole shares.

The tax that actually matters

Intuitive Surgical pays no dividend, so the 25% US withholding and annual Form 67 foreign-tax-credit dance — a recurring headache with names like Microsoft or Johnson and Johnson — does not apply here. Your entire tax exposure is on capital gains when you sell, under Section 112 (foreign shares don't get the Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 3 shares at $480 when USD/INR is 86 → cost 1,23,840 rupees. Sell 28 months later at $580 when USD/INR is 88 → proceeds 1,53,120 rupees. Taxable gain 29,280 rupees; LTCG at 12.5% = 3,660 rupees. The high headline share price matters here — a whole share at $480–$580 is a chunky retail ticket, hence fractional. The gain is computed in rupees, so a weaker rupee at sale amplifies your reported gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. For Form 67 (relevant if you also hold dividend-paying US names), see dividend withholding and Form 67.

The $60,000 estate-tax trap

Directly-held ISRG is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax. ISRG trips the threshold quickly thanks to the high per-share price: roughly a hundred shares already does it. The fix (holding through pooled or fund structures rather than direct shares) has to be a deliberate choice before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Intuitive Surgical through an ETF?

If you want…	Best route
A concentrated bet that ISRG keeps compounding ahead of medtech peers	ISRG directly
"US medical devices / surgical robotics" exposure	IHI or XHE — ISRG is a top weight
Broad US large-cap with some ISRG inside	VOO, VTI, or QQQ
Zero dividend-tax paperwork	ISRG works either way — it pays nothing
The least single-stock risk	A broad ETF

ISRG is a meaningful weight in the iShares US Medical Devices ETF (IHI) and the SPDR S&P Health Care Equipment ETF (XHE), and a smaller weight inside QQQ, VOO, and VTI. An ETF gives the same direction of travel — global procedure growth and the device cycle — with one Schedule FA entry and cleaner estate-tax treatment via pooled vehicles. Compare the routes in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: Intuitive Surgical sells and services the da Vinci robotic-assisted soft-tissue surgical platform — a near-monopoly globally. Razor-and-blade economics: a system installs for one to two million dollars, then generates recurring revenue per use (instruments and accessories at ~$600–700 per procedure, plus service contracts; recurring is ~75% of total). da Vinci 5, launched in 2024, brings improved force feedback, integrated imaging and AI, and faster turnover — kicking off a multi-year upgrade cycle on a base north of 9,500 systems. Ion (lung bronchoscopy) and SP (single-port) are early-innings adjacencies.

Bull case	Bear case
Near-monopoly installed base (9,500+ da Vinci systems)	Competition emerging — Medtronic Hugo, J&J Ottava
Instruments and accessories recurring, ~75%+ of revenue	Hospital-capital cycles can pause system sales
da Vinci 5 upgrade cycle drives multi-year capital sales	da Vinci 5 ramp execution risk
Mid-teens procedure growth in bariatric, gyn, urology	Medical-device tariffs and 2025 China exposure
Emerging-market penetration low — India, China, LatAm	Premium EV/EBITDA — little margin for slips
Ion and SP open new procedure pools	Sentiment-driven multiple — derates fast on misses

Exact valuation is in the live widget above — a near-monopoly priced for continued procedure growth and a successful da Vinci 5 ramp.

Our take

Verdict: BUY — near-monopoly platform, razor-and-blade revenue model, fresh multi-year upgrade cycle, clean no-dividend tax profile.

• Monopoly economics in a regulated category. With 9,500+ da Vinci systems installed globally, ISRG has the trained-surgeon network, case-volume data, and regulatory clearances. Rivals can launch, but rebuilding that base is a decade-long exercise — every procedure feeds the recurring instruments line.
• Long runway. da Vinci 5 refreshes the installed base in the US and Europe; India, China, and LatAm sit at a fraction of US procedures-per-capita. Ion and SP widen the addressable pool.
• Unusually clean tax profile. No dividend means no 25% US withholding, no annual Form 67, no double-tax friction — just a Section 112 decision when you sell. Fits as a core long-term holding for an Indian investor wanting US medical-devices exposure without recurring tax admin.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Competition finally has entrants: Medtronic Hugo is rolling out internationally, J&J's Ottava has slipped but will eventually launch, and Chinese platforms push locally. The moat is real but no longer uncontested — share of new placements is the metric to watch.
• Capex and tariff sensitivity: hospital capex pauses in tight budget years; medical-device tariffs on China-linked supply chains have been a 2025 swing factor.
• Valuation and sentiment: ISRG trades at a premium EV/EBITDA multiple that derates quickly on any procedure-growth wobble or da Vinci 5 stumble.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose ISRG in Schedule FA every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. No dividend means you skip Form 67, but Schedule FA is non-negotiable. Use the Schedule FA helper.
• Position size: a single medical-device leader, however monopolistic, is not an index. Size ISRG as a high-conviction satellite — the high share price means fractional ownership is how you actually rebalance.

Bottom line

Buying ISRG from India is easy and legal. What needs thought isn't the buying — it's that ISRG is a Section-112 capital-gains play (12.5% after 24 months), a US-situs asset with a $60k estate-tax trap that the high share price hits quickly, and a single name needing disciplined position sizing. Upside versus other megacap medtech: no dividend means no recurring 25% withholding and no Form 67 work. If your real thesis is "US medical devices and surgical robotics," IHI or XHE give the same direction of travel without the concentration. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.